481 related articles for article (PubMed ID: 19695388)
1. Initial experience with antiarrhythmic medication monitoring by clinical pharmacists in an outpatient setting: a retrospective review.
Snider M; Kalbfleisch S; Carnes CA
Clin Ther; 2009 Jun; 31(6):1209-18. PubMed ID: 19695388
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a pharmacist-run antiarrhythmic clinic in an ambulatory practice.
Lifer SM; Musser MR; Kier KL
J Am Pharm Assoc (2003); 2015; 55(5):546-51. PubMed ID: 26208334
[TBL] [Abstract][Full Text] [Related]
3. Clinical Pearls in Using Antiarrhythmic Drugs in the Outpatient Setting.
Parker MH; Sanoski CA
J Pharm Pract; 2016 Feb; 29(1):77-86. PubMed ID: 26602062
[TBL] [Abstract][Full Text] [Related]
4. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators.
Mason JW
N Engl J Med; 1993 Aug; 329(7):452-8. PubMed ID: 8332150
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a pharmacist-managed electrolyte protocol in outpatients on antiarrhythmic medications.
Long VP; Carnes CA; Vecchiet J; Houmsse M; Hirsch A; Snider MJ
J Am Pharm Assoc (2003); 2017; 57(4):526-531. PubMed ID: 28610942
[TBL] [Abstract][Full Text] [Related]
6. Assessment of sotalol prescribing in a community hospital: opportunities for clinical pharmacist involvement.
Finks SW; Rogers KC; Manguso AH
Int J Pharm Pract; 2011 Aug; 19(4):281-6. PubMed ID: 21733016
[TBL] [Abstract][Full Text] [Related]
7. Rationale, development, and clinical outcomes of a multidisciplinary amiodarone clinic.
Sanoski CA; Schoen MD; Gonzalez RC; Avitall B; Bauman JL
Pharmacotherapy; 1998; 18(6 Pt 2):146S-151S. PubMed ID: 9855347
[TBL] [Abstract][Full Text] [Related]
8. The impacts of a pharmacist-managed outpatient clinic and chemotherapy-directed electronic order sets for monitoring oral chemotherapy.
Battis B; Clifford L; Huq M; Pejoro E; Mambourg S
J Oncol Pharm Pract; 2017 Dec; 23(8):582-590. PubMed ID: 27733666
[TBL] [Abstract][Full Text] [Related]
9. Monitoring amiodarone's toxicities: recommendations, evidence, and clinical practice.
Stelfox HT; Ahmed SB; Fiskio J; Bates DW
Clin Pharmacol Ther; 2004 Jan; 75(1):110-22. PubMed ID: 14749697
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a pharmacist-managed amiodarone monitoring program.
Spence MM; Polzin JK; Weisberger CL; Martin JP; Rho JP; Willick GH
J Manag Care Pharm; 2011 Sep; 17(7):513-22. PubMed ID: 21870892
[TBL] [Abstract][Full Text] [Related]
11. Frequency of Adverse Event Monitoring in Ambulatory Patients on Amiodarone or Dofetilide.
Rickard JP; Negrelli J; Olson JL; Dick T
J Pharm Pract; 2018 Oct; 31(5):457-461. PubMed ID: 28884613
[TBL] [Abstract][Full Text] [Related]
12. Potentially significant drug interactions of class III antiarrhythmic drugs.
Yamreudeewong W; DeBisschop M; Martin LG; Lower DL
Drug Saf; 2003; 26(6):421-38. PubMed ID: 12688833
[TBL] [Abstract][Full Text] [Related]
13. Cost-benefit and cost-savings analyses of antiarrhythmic medication monitoring.
Snider M; Carnes C; Grover J; Davis R; Kalbfleisch S
Am J Health Syst Pharm; 2012 Sep; 69(18):1569-73. PubMed ID: 22935939
[TBL] [Abstract][Full Text] [Related]
14. A benefit-risk assessment of class III antiarrhythmic agents.
Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L
Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126
[TBL] [Abstract][Full Text] [Related]
15. Use of a combination of class III and class Ic antiarrhythmic agents in patients with electrical storm.
Fuchs T; Groysman R; Meilichov I
Pharmacotherapy; 2008 Jan; 28(1):14-9. PubMed ID: 18154469
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Pharmacist-Led Amiodarone Monitoring Services on Improving Adherence to Amiodarone Monitoring Recommendations: A Systematic Review.
Dixon DL; Dunn SP; Kelly MS; McLlarky TR; Brown RE
Pharmacotherapy; 2016 Feb; 36(2):230-6. PubMed ID: 26846446
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a program for outpatient sotalol loading with physician and pharmacist monitoring.
Roberts C; Sherry M; Labreck M; Amin A; Sullivan D
J Am Pharm Assoc (2003); 2022; 62(5):1700-1706. PubMed ID: 35725728
[TBL] [Abstract][Full Text] [Related]
18. Updates in antiarrhythmic therapy for atrial fibrillation in geriatric patients.
Ehrlich C; Tsu LV
Consult Pharm; 2015 Feb; 30(2):82-91. PubMed ID: 25695414
[TBL] [Abstract][Full Text] [Related]
19. One-year treatment persistence and potential adverse events among patients with atrial fibrillation treated with amiodarone or sotalol: a retrospective claims database analysis.
Kim MH; Smith PJ; Jhaveri M; Lin J; Klingman D
Clin Ther; 2011 Nov; 33(11):1668-1681.e1. PubMed ID: 22108302
[TBL] [Abstract][Full Text] [Related]
20. Impact of a Pharmacy-Cardiology Collaborative Practice on Dofetilide Safety Monitoring.
Quffa LH; Panna M; Kaufmann MR; McKillop M; Dietrich NM; Franck AJ
Ann Pharmacother; 2017 Jan; 51(1):39-43. PubMed ID: 27630191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
